0001651308-21-000126.txt : 20210621
0001651308-21-000126.hdr.sgml : 20210621
20210621164553
ACCESSION NUMBER: 0001651308-21-000126
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210616
FILED AS OF DATE: 20210621
DATE AS OF CHANGE: 20210621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huang Jane
CENTRAL INDEX KEY: 0001683913
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37686
FILM NUMBER: 211031379
MAIL ADDRESS:
STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES
STREET 2: 94 SOLARIS AVENUE
CITY: CAMANA BAY, GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BeiGene, Ltd.
CENTRAL INDEX KEY: 0001651308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981209416
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
STREET 2: 94 SOLARIS AVENUE, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
BUSINESS PHONE: 13459494123
MAIL ADDRESS:
STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
STREET 2: 94 SOLARIS AVENUE, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
4
1
wf-form4_162430832547020.xml
FORM 4
X0306
4
2021-06-16
0
0001651308
BeiGene, Ltd.
BGNE
0001683913
Huang Jane
C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
94 SOLARIS AVENUE
CAMANA BAY, GRAND CAYMAN
E9
KY1-1108
CAYMAN ISLANDS
0
1
0
0
CMO, Hematology
Ordinary Shares
2021-06-16
4
A
0
25350
0
A
304186
D
American Depositary Shares
2021-06-18
4
S
0
469
325.6568
D
0
D
Share Option (Right to Buy)
26.53
2021-06-16
4
A
0
157196
0
A
2031-06-15
Ordinary Shares
157196.0
157196
D
Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.
/s/ Qing Nian, as Attorney-in-Fact
2021-06-21